Reporting owner · Q3 2026 · CIK 1722140

Ceesay Abraham: insider trades.

Ceesay Abraham reported 17 non-derivative transactions on 7 SEC ownership filings in Q3 2026: 0 open-market purchases and 17 sales ($4.6M), across 1 company.

Transactions
17
Purchases (P)
0
Sales (S)
17
Companies
1
Name as filed
Ceesay Abraham

Companies

CompanyRelationshipTransactions
Rapport Therapeutics, Inc. (RAPP)Director, Officer · Chief Executive Officer17

Transactions

17 non-derivative rows. Shares and prices as filed.
DateCompanyCodeSharesPriceOwned afterFiling
2026-09-23Rapport Therapeutics, Inc.S43$41.05456,767Form 4
2026-09-23Rapport Therapeutics, Inc.S1,952$39.05457,025Form 4
2026-09-23Rapport Therapeutics, Inc.S215$39.86456,810Form 4
2026-09-08Rapport Therapeutics, Inc.S7,141$45.56460,046Form 4
2026-09-08Rapport Therapeutics, Inc.S1,069$46.01458,977Form 4
2026-08-25Rapport Therapeutics, Inc.S18,921$49.57467,187Form 4
2026-08-11Rapport Therapeutics, Inc.S3,664$46.9511,402Form 4
2026-08-11Rapport Therapeutics, Inc.S19,500$48.04491,902Form 4
2026-08-11Rapport Therapeutics, Inc.S5,794$48.62486,108Form 4
2026-08-10Rapport Therapeutics, Inc.S14,171$45.97523,436Form 4
2026-08-10Rapport Therapeutics, Inc.S8,370$46.75515,066Form 4
2026-07-27Rapport Therapeutics, Inc.S2,203$42.11537,614Form 4
2026-07-27Rapport Therapeutics, Inc.S7$42.74537,607Form 4
2026-07-14Rapport Therapeutics, Inc.S2,729$40.57539,817Form 4
2026-07-14Rapport Therapeutics, Inc.S5,481$39.72542,546Form 4
2026-06-29Rapport Therapeutics, Inc.S876$40.34548,027Form 4
2026-06-29Rapport Therapeutics, Inc.S7,344$39.77548,903Form 4

Questions

What stock did Ceesay Abraham buy or sell?

Ceesay Abraham reported 17 non-derivative transactions on 7 SEC ownership filings in Q3 2026: 0 open-market purchases and 17 sales ($4.6M), across 1 company.

Is Ceesay Abraham the same person as other filers with this name?

This page covers SEC CIK 1722140 only. The SEC assigns each reporting owner a CIK, and people with the same name have different CIKs.

Source: SEC Insider Transactions Data Sets, Q3 2026. Reported as filed; we do not assess intent, performance or compliance. All filings for this CIK on SEC.gov.

Plain-text version for agents and LLMs: /insiders/ceesay-abraham-1722140.md

Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.